# US 2018/0021274 A1 · Compositions comprising beta-hydroxybutyric acid and salt, and methods of using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021274 A1
- Document ID: US20180021274A1
- Status: Published application
- Kind: A1
- Application number: 15/470,179
- Filed: 2017-03-27
- Published: 2018-01-25
- Earliest claimed: 2016-07-21
- Assignees: Savind, Inc.
- Applicants: SavInd, Inc.
- Inventors: Patrick Arnold
- Web page: https://patentgrep.com/patent/US20180021274A1

## CPC

- A61K 31/191: having two or more hydroxy groups, e.g. gluconic acid
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

β-hydroxybutyric acid in combination with β-hydroxybutyrate salts are useful to induce ketosis, achieving blood ketone levels of (0.5-6.0 mmol/L), with or without dietary restriction, and without inducing harmfully high mineral loads in the blood. The combination of β-hydroxybutyric acid and salt results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance & endurance in a short period of time. Further, use of these supplements to achieve ketosis yields a significant elevation of blood ketones and reduction of blood glucose levels. These acid/salt mixtures are also useful for suppressing appetite, preventing epileptic seizures, and treating cancer.

## Claims

### Claim 1

A composition comprising ii-hydroxybutyric free acid and β-hydroxybutyrate salt, wherein the free acid and salt stand in a mass:mass ratio from ˜125 parts free acid: ˜7 parts salt to ˜0.4 parts free acid: ˜125.1 parts salt.

### Claim 1 (depends on 1)

ering to the individual an aqueous solution of the composition of claim 1.

### Claim 1 (depends on 1)

tion of claim 1 to an epileptic patient.

### Claim 1 (depends on 1)

tion of claim 1 to a cancer patient.

### Claim 1 (depends on 1)

of the composition of claim 1 to an individual.

### Claim 1 (depends on 1)

position of claim 1 to an individual.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the pH of the composition is about 3.2 to about 8.0 in a 50% (w/v) aqueous solution.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the pH of the composition is about 4.0 to about 6.0.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the pH of the composition is about 4.0 to about 5.0.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the pH of the composition is about 4.5.

### Claim 6 (depends on 2)

The composition of claim 2, wherein the salt is selected from one or more of calcium magnesium, potassium, and sodium salts.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the composition comprises both D and L isomers of β-hydroxybutyric free acid and/or β-hydroxybutyrate salt.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the β-hydroxybutyric free acid and/or β-hydroxybutyrate salt is/are present as a racemic mixture.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the composition is a dry powder.

### Claim 10 (depends on 9)

The composition of claim 9, wherein β-hydroxybutyric free acid and β-hydroxybutyrate salt are each present as D isomer.

### Claim 11 (depends on 6)

The composition of claim 6, wherein the salt is selected from potassium and sodium salts.

### Claim 11 (depends on 11)

omposition of claim 11, wherein the salt is a mixture of potassium and sodium salts.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the free acid and salt stand in a mass:mass:mass ratio from ˜125 parts free acid: ˜3.7 parts potassium salt: ˜3.3 parts sodium salt to ˜0.4 parts free acid: ˜66.3 parts potassium salt: ˜58.8 parts sodium salt.

### Claim 14 (depends on 13)

The composition of claim 13, wherein the mass:mass:mass ratio is ˜75 parts free acid: ˜30.5 parts potassium salt: ˜27 parts sodium salt.

### Claim 15 (depends on 9)

A pharmaceutical dosage form comprising the dry powder of claim 9, wherein the pharmaceutical dosage form is a table or a capsule.

### Claim 16

A method of inducing ketosis in an individual in need thereof, the method comprising

### Claim 17 (depends on 16)

The method of claim 16, wherein the pH of the composition is about 3.2 to about 8.0 in a ˜50% (w/v) aqueous solution.

### Claim 18 (depends on 17)

The method of claim 17, wherein the pH is about 4.5.

### Claim 19 (depends on 18)

The method of claim 18, wherein the salt is a mixture of potassium and sodium salts.

### Claim 20 (depends on 19)

The method of claim 19, wherein the free acid and salt stand in a mass:mass:mass ratio from ˜125 parts free acid: ˜3.7 parts potassium salt: ˜13 parts sodium salt to ˜0.4 parts free acid: ˜66.3 parts potassium salt: ˜58.8 parts sodium salt.

### Claim 21 (depends on 20)

The method of claim 20, wherein the mass:mass:mass ratio is ˜75 parts free acid: ˜30.5 parts potassium salt: ˜27 parts sodium salt.

### Claim 22 (depends on 16)

The method of claim 16, wherein the mineral load of the individual is reduced by at least about 40% relative to the mineral load that the same individual would display after consuming a 50% (w/v) aqueous solution of β-hydroxybutyrate potassium and sodium salts in a mass:mass ratio of 2.9 parts potassium salt to 2.5 parts sodium salt.

### Claim 23

A method of treating epilepsy, the method comprising administering an effective amount of the

### Claim 24

A method of treating cancer, the method comprising administering an effective amount of the

### Claim 25

A method of increasing athletic endurance, the method comprising administering an effective

### Claim 26

A method of suppressing appetite, the method comprising administering an effective amount of

### Claim 27 (depends on 1, 26)

The method of claim 26, wherein the body weight of the individual is less at a time one month after the administration than it is at the time of administration. method of treating diabetes, the method comprising administering an effective amount of the composition of claim 1 to a diabetic patient.

### Claim 29 (depends on 28)

The method of claim 28, wherein average blood glucose concentration is at least 5% less in the patient at a time one week after the administration than it is on the day before administration.
